[{"id":"fdae9b28-c98e-424b-b904-db41eb7115d7","acronym":"KISS01","url":"https://clinicaltrials.gov/study/NCT06651203","created_at":"2025-02-26T15:11:32.230Z","updated_at":"2025-02-26T15:11:32.230Z","phase":"","brief_title":"Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study","source_id_and_acronym":"NCT06651203 - KISS01","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" CD4 • KIR3DL2 • DPP4","pipe":"","alterations":" ","tags":["CD4 • KIR3DL2 • DPP4"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2024-10-21"},{"id":"daf19f0a-7b6b-41f2-9b88-5ae24267cacb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05321147","created_at":"2023-02-22T16:01:05.272Z","updated_at":"2024-07-02T16:35:12.412Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2","source_id_and_acronym":"NCT05321147","lead_sponsor":"Innate Pharma","biomarkers":" KIR3DL2","pipe":"","alterations":" ","tags":["KIR3DL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lacutamab (IPH4102)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/17/2022","start_date":" 03/17/2022","primary_txt":" Primary completion: 11/19/2023","primary_completion_date":" 11/19/2023","study_txt":" Completion: 02/08/2024","study_completion_date":" 02/08/2024","last_update_posted":"2024-03-28"},{"id":"5c741a0e-16cd-4f46-91af-8ec7997f60f5","acronym":"KILT","url":"https://clinicaltrials.gov/study/NCT04984837","created_at":"2021-08-02T15:53:19.881Z","updated_at":"2024-07-02T16:35:27.025Z","phase":"Phase 2","brief_title":"Study of Lacutamab in Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT04984837 - KILT","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" KIR3DL2","pipe":"","alterations":" ","tags":["KIR3DL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • lacutamab (IPH4102)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2027","study_completion_date":" 01/30/2027","last_update_posted":"2023-12-05"},{"id":"bdc56d71-0fa3-40c1-a0b7-78ba95778d63","acronym":"TELLOMAK","url":"https://clinicaltrials.gov/study/NCT03902184","created_at":"2021-01-18T19:12:46.739Z","updated_at":"2024-07-02T16:35:42.992Z","phase":"Phase 2","brief_title":"IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma","source_id_and_acronym":"NCT03902184 - TELLOMAK","lead_sponsor":"Innate Pharma","biomarkers":" KIR3DL2","pipe":"","alterations":" ","tags":["KIR3DL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lacutamab (IPH4102)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 05/22/2019","start_date":" 05/22/2019","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2023-07-14"},{"id":"b849a17b-d08c-4390-b27f-0a1da7ac0a61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02593045","created_at":"2021-01-18T12:35:03.125Z","updated_at":"2024-07-02T16:36:35.865Z","phase":"Phase 1","brief_title":"Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)","source_id_and_acronym":"NCT02593045","lead_sponsor":"Innate Pharma","biomarkers":" CD4 • KIR3DL2","pipe":"","alterations":" ","tags":["CD4 • KIR3DL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lacutamab (IPH4102)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2021-01-20"},{"id":"84c7440b-f268-415f-b8ba-2a59064146fa","acronym":"DIAPREMYF","url":"https://clinicaltrials.gov/study/NCT02539472","created_at":"2022-06-03T03:59:41.116Z","updated_at":"2024-07-02T16:37:32.706Z","phase":"","brief_title":"Early Diagnosis of Mycosis Fungoides","source_id_and_acronym":"NCT02539472 - DIAPREMYF","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" KIR3DL2 • KIR3DL1","pipe":"","alterations":" ","tags":["KIR3DL2 • KIR3DL1"],"overall_status":"Unknown status","enrollment":" Enrollment 620","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 11/01/2017","study_completion_date":" 11/01/2017","last_update_posted":"2016-04-18"}]